Novo Nordisk raises 2026 outlook after Q3 profit beat and strong obesity drug sales
Novo Nordisk reported Q3 2026 adjusted operating profit of DKK 31.7 billion, up 27% at constant exchange rates, while reported profit fell 9% due to impairment charges. Obesity‑treatment sales jumped 22% at CER, driven by Wegovy and Ozempic launches. The company lifted its full‑year guidance for adjusted sales and operating profit to a range of –2% to +2% at CER, up from a prior outlook of –6% to 0%. CEO Mike Doustdar noted seasonal flattening of Wegovy prescriptions but expects a pick‑up around the holidays.
Why it matters
The upgraded guidance expands the upside potential for Novo Nordisk’s earnings, as analysts now model a neutral to modest growth path for 2026 rather than a decline. The price cuts announced for Wegovy and Ozempic in the U.S. starting Jan 1 may affect cash flow but are intended to sustain market share, which could influence investor sentiment and valuation.
Key facts
- 1Adjusted operating profit was DKK 31.720 billion, up 27% at constant exchange rates from the prior year. stocktitan.net
- 2Reported operating profit was DKK 23.011 billion, down 9% at constant exchange rates due to DKK 8.7 billion of non‑cash impairment charges. stocktitan.net
- 3Obesity‑treatment sales increased 22% at constant exchange rates, contributing DKK 26.146 billion to Q3 net sales. econotimes.com
- 4Q3 net sales were DKK 79.195 billion, up 4% at constant exchange rates. econotimes.com
- 5Full‑year adjusted sales and operating profit guidance was revised to –2% to +2% at constant exchange rates, from a prior range of –6% to 0%. rte.ie
- 6Wegovy pill sales in Q3 were DKK 5.39 billion, up 53% from the prior quarter. rte.ie
Summary written by AlphAI AI Desk from 20 of 35 sources. Not investment advice. Figures are as stated by the linked sources.